Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 11/20 | 0.45 |
| ▸ | SRC | P12931 | 8/20 | 0.45 |
| ▸ | XDH | P47989 | 3/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30982318 | 0.84 | XDH (0.47) | ABL1SRCXDHALOX15MAPK1 | |
| SCHEMBL25268349 | 0.84 | XDH (0.47) | ABL1SRCXDHALOX15MAPK1 | |
| SCHEMBL27348023 | 0.84 | ALOX15 (0.63) | ALOX15MAPT | |
| SCHEMBL25431660 | 0.82 | XDH (0.48) | ABL1SRCXDHMAPK1CYP1A2 | |
| SCHEMBL10322137 | 0.81 | DYRK1A (0.43) | MAPT | |
| SCHEMBL1824752 | 0.81 | GPR35 (0.51) | ALOX15MAPK1CYP1A2MAPT | |
| SCHEMBL30189371 | 0.81 | GPR35 (0.51) | ALOX15MAPK1CYP1A2MAPT | |
| SCHEMBL30204895 | 0.80 | CDK2 (0.41) | ALOX15MAPT | |
| SCHEMBL2328622 | 0.77 | ABL1 (0.58) | ABL1SRC | |
| SCHEMBL18940570 | 0.77 | ABL1 (0.49) | ABL1SRCXDHMAPK1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2197438-B1 | HETEROCYCLIC COMPOUNDS AS CRTH2 RECEPTOR ANTAGONISTS | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY SHIJIAZHUAN (CN) | 2015-07-15 | — | — | EP | disclosed |
| EP-2197438-B1 | HETEROCYCLIC COMPOUNDS AS CRTH2 RECEPTOR ANTAGONISTS | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY SHIJIAZHUAN (CN) | 2015-07-15 | — | — | EP | disclosed |
| US-8772312-B2 | Heterocyclic compounds as CRTH2 receptor antagonists | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2014-07-08 | — | — | US | disclosed |
| US-8772312-B2 | Heterocyclic compounds as CRTH2 receptor antagonists | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2014-07-08 | — | — | US | disclosed |
| US-8772312-B2 | Heterocyclic compounds as CRTH2 receptor antagonists | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2014-07-08 | — | — | US | disclosed |
| US-20100222270-A1 | HETEROCYCLIC COMPOUNDS AS CRTH2 RECEPTOR ANTAGONISTS | CHEMETEK, LLC | 2010-09-02 | — | — | US | disclosed |
| US-20100222270-A1 | HETEROCYCLIC COMPOUNDS AS CRTH2 RECEPTOR ANTAGONISTS | CHEMETEK, LLC | 2010-09-02 | — | — | US | disclosed |
| US-20100222270-A1 | HETEROCYCLIC COMPOUNDS AS CRTH2 RECEPTOR ANTAGONISTS | CHEMETEK, LLC | 2010-09-02 | — | — | US | disclosed |
| EP-2197438-A1 | HETEROCYCLIC COMPOUNDS AS CRTH2 RECEPTOR ANTAGONISTS | Chemietek, Llc (US) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009049021-A1 | HETEROCYCLIC COMPOUNDS AS CRTH2 RECEPTOR ANTAGONISTS | CHEMIETEK, LLC (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222270-A1 | HETEROCYCLIC COMPOUNDS AS CRTH2 RECEPTOR ANTAGONISTS | HRH2, NR3C2, HRH1 | ABL1 3041/4885SRC 1616/4885XDH 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.